PT  - JOURNAL ARTICLE
AU  - Alexander Neumann
AU  - Jean-Baptiste Pingault
AU  - Janine F. Felix
AU  - Vincent W. V. Jaddoe
AU  - Henning Tiemeier
AU  - Charlotte Cecil
AU  - Esther Walton
TI  - Epigenome-wide contributions to individual differences in childhood phenotypes: A GREML approach
AID  - 10.1101/2021.06.24.21259449
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.24.21259449
4099  - http://medrxiv.org/content/early/2021/06/29/2021.06.24.21259449.short
4100  - http://medrxiv.org/content/early/2021/06/29/2021.06.24.21259449.full
AB  - Background DNA methylation is an epigenetic mechanism involved in human development. Numerous epigenome-wide association studies (EWAS) have investigated the associations of DNA methylation at single CpG sites with childhood outcomes. However, the overall contribution of DNA methylation across the genome (R2Methylation) towards childhood phenotypes is unknown. An estimate of R2Methylation would provide context regarding the importance of DNA methylation explaining variance in health outcomes.Methods We estimated the variance explained by epigenome-wide cord blood methylation (R2Methylation) for five childhood phenotypes: gestational age, birth weight, and body mass index (BMI), IQ and ADHD symptoms at school age. We adapted a genome-based restricted maximum likelihood (GREML) approach with cross-validation (CV) to DNA methylation data and applied it in two population-based birth cohorts: ALSPAC (n=775) and Generation R (n=1382).Results Using information from >470,000 autosomal probes we estimated that DNA methylation at birth explains 45% (SDCV = 0.07) of gestational age variance and 16% (SDCV = 0.05) of birth weight variance. The R2Methylation estimates for BMI, IQ and ADHD symptoms at school age estimates were near 0% across almost all cross-validation iterations.Conclusions The results suggest that cord blood methylation explains a moderate to large degree of variance in gestational age and birth weight, in line with the success of previous EWAS in identifying numerous CpG sites associated with these phenotypes. In contrast, we could not obtain a reliable estimate for school-age BMI, IQ and ADHD symptoms. This may reflect a null bias due to insufficient sample size to detect variance explained in more weakly associated phenotypes, although the true R2Methylation for these phenotypes is likely below that of gestational age and birth weight when using DNA methylation at birth.Competing Interest StatementThe authors have declared no competing interest.Funding StatementALSPACThe UK Medical Research Council (MRC) and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and EW will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Methylation data in the ALSPAC cohort were generated as part of the UK BBSRC funded (BB/I025751/1 and BB/I025263/1) Accessible Resource for Integrated Epigenomic Studies (ARIES, http://www.ariesepigenomics.org.uk). EW was partially funded by the Bath Institute for Mathematical Innovation. EW is also funded by the European Unions Horizon 2020 research and innovation programme (grant nr. 848158) and by CLOSER, whose mission is to maximise the use, value and impact of longitudinal studies. CLOSER was funded by the Economic and Social Research Council (ESRC) and the Medical Research Council (MRC) between 2012 and 2017. Its initial five year grant has since been extended to March 2021 by the ESRC (grant reference: ES/K000357/1). The funders took no role in the design, execution, analysis or interpretation of the data or in the writing up of the findings. www.closer.ac.uk.GENRThe general design of the Generation R Study is made possible by financial support from Erasmus MC, University Medical Center Rotterdam, Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw) and the Ministry of Health, Welfare and Sport. The EWAS data was funded by a grant from the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA; project nr. 050-060-810), by funds from the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, and by a grant from the National Institute of Child and Human Development (R01HD068437). A. Neumann and H. Tiemeier are supported by a grant of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant No. 024.001.003, Consortium on Individual Development). A. Neumann is also supported by a Canadian Institutes of Health Research team grant. The work of H. Tiemeier is further supported by a NWO-VICI grant (NWO-ZonMW: 016.VICI.170.200). The work of CC has received funding from the European Unions Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 707404.This project received funding from the European Unions Horizon 2020 research and innovation programme (733206, LifeCycle; 633595, DynaHEALTH; 848158, EarlyCause, 874739, LongITools)) and from the European Joint Programming Initiative A Healthy Diet for a Healthy Life (JPI HDHL, NutriPROGRAM project, ZonMw the Netherlands no.529051022 and PREcisE project ZonMw the Netherlands no.529051023).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ALSPAC: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.GenR: All parents gave informed consent for their children's participation. The Generation R Study is conducted in accordance with the Declaration of Helsinki. Study protocols were approved by the Ethics Committee of Erasmus MC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during the current study are not publicly available to ensure participant privacy and compliance with Dutch and UK law, but are available on reasonable request. For Generation R data, please contact management (datamanagementgenr{at}erasmusmc.nl) and the corresponding author. For ALSPAC, please see http://www.bristol.ac.uk/alspac/researchers/ for instructions on data access. https://generationr.nl/researchers/collaboration/ (EWAS)Epigenome-wide association studies(BMI)Body mass index(CV)Cross-validation(DNAm)DNA methylation(M)Methylation similarity matrix(G)Genetic relatedness matrix